Zymeworks Inc. $ZYME Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in Zymeworks Inc. (NASDAQ:ZYME) by 8.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 2,328,727 shares of the company’s stock after acquiring an additional 174,293 shares during the period. Vanguard Group Inc.’s holdings in Zymeworks were worth $61,315,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in ZYME. AQR Capital Management LLC increased its position in shares of Zymeworks by 86.0% in the 1st quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock valued at $577,000 after acquiring an additional 22,411 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Zymeworks by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock valued at $386,000 after acquiring an additional 1,427 shares during the period. Jane Street Group LLC increased its position in shares of Zymeworks by 487.0% in the 1st quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock valued at $1,617,000 after acquiring an additional 112,636 shares during the period. Creative Planning increased its position in shares of Zymeworks by 114.8% in the 2nd quarter. Creative Planning now owns 25,389 shares of the company’s stock valued at $319,000 after acquiring an additional 13,567 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Zymeworks by 1,050.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock valued at $5,543,000 after acquiring an additional 403,281 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks News Roundup

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Zymeworks authorized a new 2026 share repurchase program for up to $125 million, a move that can boost shareholder value and support the stock. Article Title
• Positive Sentiment: The company affirmed liquidity while ending the prior repurchase program after buying back a meaningful amount of stock, reinforcing balance-sheet confidence. Article Title
• Neutral Sentiment: HC Wainwright updated its earnings estimates for Zymeworks, raising FY2026 and Q3 2026 forecasts while trimming Q2 2026 and Q4 2026 estimates; the firm kept a Buy rating and $46 price target.
• Neutral Sentiment: Zymeworks also announced upcoming investor conference appearances, which should help keep the company visible to investors but is not, by itself, a major catalyst. Article Title
• Negative Sentiment: The latest earnings-related coverage noted a mix of progress and pressure, underscoring that the company is still navigating uneven near-term fundamentals despite its longer-term pipeline story. Article Title

Zymeworks Stock Down 2.5%

ZYME stock opened at $23.96 on Friday. The company’s 50-day simple moving average is $25.65 and its 200-day simple moving average is $24.28. Zymeworks Inc. has a 52-week low of $10.93 and a 52-week high of $29.75. The firm has a market cap of $1.75 billion, a P/E ratio of -17.49 and a beta of 1.20.

Zymeworks (NASDAQ:ZYME) last posted its earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%.The firm had revenue of $2.41 million for the quarter. On average, analysts anticipate that Zymeworks Inc. will post 1.64 earnings per share for the current fiscal year.

Zymeworks announced that its board has initiated a stock repurchase program on Thursday, May 14th that permits the company to buyback $125.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 7% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

ZYME has been the topic of several research reports. Wells Fargo & Company upped their target price on Zymeworks from $33.00 to $34.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Truist Financial raised Zymeworks to a “strong-buy” rating in a research report on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research report on Monday, April 20th. Stifel Nicolaus upped their price target on shares of Zymeworks from $40.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Finally, Leerink Partners upped their price target on shares of Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zymeworks presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Zymeworks Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.